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Background: Mozambique adopted artemisinin-based combination therapy (ACT) for the treatment of uncomplicated
Plasmodium falciparum malaria in the year 2006, and since 2009 artemether-lumefantrine (AL) and artesunate-
amodiaquine (ASAQ) have been proposed as alternative first-line treatments. A multicentre study was conducted in five
sites across the country to assess the in vivo efficacy and tolerability of these two drugs.
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all cases of recurrent parasitaemia from day 7 onwards to distinguish recrudescence from re-infection.
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to the study. Day 28 PCR-corrected efficacy for AL was 96.0% (335/339; 95% CI: 93.4-97.8), while for ASAQ it was 99.6%
(232/233; 95% CI: 97.6-99.9). The majority of recurring parasitaemia cases throughout follow-up were shown to be
re-infections by PCR. Both drugs were well tolerated, with the most frequent adverse event being vomiting (AL 4.5%
[20/439]; ASAQ 9.6% [25/261]) and no significant events deemed related to the study drugs.
Conclusion: This study confirms that both AL and ASAQ remain highly efficacious and well tolerated for the treatment
of uncomplicated malaria in Mozambican children. Studies such as these should be replicated regularly in the selected
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The last decade has seen a true revolution regarding the
diagnosis and treatment of malaria, globally. In sub-Saharan
Africa, malaria-endemic countries have progressively
replaced, as a consequence of the growing parasite resist-
ance and the associated resurgence in infection rates and
malaria-related morbidity and mortality [1], conventional
anti-malarial drugs by faster acting and more efficacious anti-
malarials. Indeed, artemisinin-based combination therapy
(ACT), recommended by the World Health Organization
(WHO) since the beginning of this millennium [2], have now
been widely adopted in all African countries for the treatment
of Plasmodium falciparum malaria, a change that has po-
sitively contributed to the improved global burden of
malaria [3].
In Mozambique, malaria remains a major cause of disease
and death, putting an overwhelming pressure on the under-
staffed and fragile health system [4,5]. National guidelines
for the treatment of malaria have experienced various ad-
justments since the abandoning of chloroquine in the year
2003, and the introduction of sulphadoxine-pyrimethamine
(SP) plus amodiaquine. In 2006, this combination was again
modified to SP + artesunate and in 2009 to artemether-
lumefantrine with artesunate-amodiaquine being considered
an alternative first line treatment recommendation [6].
Routine surveillance of in vivo efficacy of currently
used drugs together with evaluation of the prevalence of
molecular markers associated with parasite resistance to
anti-malarials is mandatory to assess the adequacy of
current treatment recommendations and guarantee a
timely response to the emergence of parasite resistance.
This is particularly imperative now in relation to the re-
cent documentation in Southeast Asia of the emergence
and potential spread of parasite resistance to artemisi-
nins [7-9]. However, only a handful of clinical trials [10-13],
and all of them conducted in the same site (Manhiça, south-
ern part of the country), have assessed the in vivo efficacy of
ACTs in Mozambique over the last several years, describing
efficacy estimates (day 28, PCR-corrected,) for combinations
such as artemether-lumefantrine; artesunate-amodiaquine
(ASAQ), dihydroartemisinin-piperaquine (DHA-PQP), or SP
always exceeding 93% [10,12,13].
In this study, conducted from June 2011 to the end of
2012, in five sentinel sites across the country, the in vivo effi-
cacy and safety of artemether-lumefantrine (AL; Coartem™)
and ASAQ (Winthrop), the two currently recommended
ACT in the country, were assessed for the treatment of un-
complicated P. falciparum malaria in Mozambican children
between six and 59 months of age.
Methods
Study sites and malaria in Mozambique
The study was conducted using the standard WHO
in vivo efficacy protocol [14] in five hospitals or healthcentres across Mozambique, namely: 1) Hospital Rural
de Montepuez, in Cabo Delgado province (northern re-
gion); 2) Centro de Saúde de Dondo, in Sofala province
(central region); 3) Hospital provincial de Tete, in Tete
province (central region); 4) Hospital rural de Chokwe,
in Gaza province (southern region); and 5) Hospital dis-
trital de Manhiça, in Maputo province (southern re-
gion). Malaria transmission in Mozambique is perennial,
with a peak transmission period normally coinciding
with the rainy season, from November to April. Study
cohort 1 testing AL began in June 2011 and involved the
five sites, while study cohort 2 assessing the combination
ASAQ started in August 2012, once the follow-up for
the first cohort had been concluded, and was only con-
ducted in three of the five sites (Montepuez, Dondo and
Chokwe).
Patients
The study population comprised children aged six to
59 months with microscopically confirmed, acute un-
complicated malaria. Other inclusion criteria included
body weight ≥5 kg, the presence of fever (≥37.5°C axil-
lary) or a history of fever in the preceding 24 hours, P.
falciparum malaria mono-infection with an asexual
blood density ≥2,000/μL and <200,000/μL, and the ab-
sence of severe signs of complicated malaria as defined
by WHO [15]. Key exclusion criteria included mixed
malarial infections, haemoglobin <5 g/dL, severe mal-
nutrition, intake of anti-malarials within the preceding
seven days, ongoing prophylaxis in HIV-positive patients
with cotrimoxazole or the intake of any other drug with
anti-malarial activity, and any serious underlying disease.
Patients satisfying the inclusion criteria were enrolled if
the parent/guardian signed a detailed written informed
consent.
Treatment
Eligible patients were consecutively assigned to the cohort
and treated with AL (cohort 1) or ASAQ (cohort 2). AL
(Coartem™, Novartis, each tablet contains 20 mg arte-
mether and 120 mg lumefantrine) was administered twice
daily for three days (six doses in total) with dosage de-
termined according to body weight: one tablet for children
5 to <15 kg, two tablets for children 15 to <25 kg, and
three tablets children 25 to <35 kg. ASAQ (Winthrop™,
Sanofi Aventis, each tablet contains 25 mg artesunate and
67.5 mg amodiaquine) was administered once daily
according to body weight: one tablet tablet for chil-
dren <9 kg, two tablets for children 9–17.9 kg; and four
tablets for children >18-35 kg. All treatments were directly
observed for a minimum of 30 min. Vomiting occurring
within the first 30 min implied the repetition of the full
dose of treatment. For those patients living far away from
the health facilities, and for which direct observation of
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offered for the first three days of the study.
Antipyretics, such as paracetamol, were used to con-
trol fever > = 38°C. In the event of severe malaria or dan-
ger signs, the patient was hospitalized and received
intravenous quinine, according to the national malaria
treatment policy. Rescue therapy according to national
malaria treatment guidelines was also administered in
cases of early or late treatment failure with parenteral
quinine [16].
Evaluation
Follow-up visits took place on days 1, 2, 3, 7, 14, 21 and
28 after enrolment or at any time point whenever the
child was sick. Patients who prematurely discontinued
either study drug or the study were excluded from the
study. Vital signs and body temperature were assessed
during each follow-up visit. Adverse events were re-
corded and assessed for severity and association with
study medication.
Thick and thin Giemsa-stained blood slides were pre-
pared before each dose was administered and at every
follow-up visit of days 2, 3, 7, 14, 21, and 28. Slides were
examined by two independent microscopists and consid-
ered negative if no parasites were seen after examination
of 200 oil-immersion fields in a thick blood film. Para-
site density was estimated by counting the number of
asexual parasites in 200 white blood cells (WBC), assum-
ing a standard WBC count of 8,000 /μl. Species determin-
ation (and thus conformation of mono-infection) was
made based on assessment of thin films. Blood spots forFigure 1 Study profile in both study cohorts.PCR analysis were collected from every patient using 3 M
Whatman™ filter papers at baseline and at days 7, 14, 21
and 28, day of treatment failure or at any other unsched-
uled visit, and subsequently stored in plastic zip bags con-
taining silica gel dessicant. PCR was performed centrally
for all cases of recurrent parasitaemia from day 7 onwards,
including DNA extraction using a QIAamp DNA Mini Kit
(Qiagen), and investigation of the three polymorphic gen-
etic markers MSP1, MSP2, and GluRP, which were used
to distinguish recrudescence from new infections, accord-
ing to WHO recommended procedures [17]. Recrudes-
cence was defined as at least one identical allele for each
of the three markers in the pre-treatment and post-
treatment samples. New infections were diagnosed when
all alleles for at least one of the markers differed between
the two samples. Cases with new infection were excluded
from the analysis.
Study outcomes
The primary efficacy outcomes were the PCR-corrected
early treatment failure (ETF), late clinical failure (LCF),
late parasitological failure (LPF) and adequate clinical
and parasitological response (ACPR) at day 28. Second-
ary outcomes included 28 day-uncorrected ACPR (crude
efficacy), safety and tolerability profiles, time to parasite,
fever and gametocyte clearance, and haemoglobin changes
from baseline to day 28.
Data management and statistical analysis
Data were recorded using specifically designed, standard-
ized case report forms based on those proposed by WHO
Table 1 Baseline characteristics of enrolled subjects
according to study cohort (treatments received AL and





Variable N = 439 N = 261
Female gender n (%) 197 (45) 137 (52)
Age in years (mean ± SD) 2.5 ± 1.2 2.5 ± 1.3
Weight in kg (mean ± SD) 11.8 ± 2.9 12.2 ± 3.7
Fever n (%) 319 (73) 201 (77)







Hb in g/dL (mean ± SD) 9.2 ± 2.0 9.0 ± 1.8
Table 2 Treatment outcomes on day 28, according to study c
Cohort 1: Artemether-Lumefantrine Montepuez Dondo
Variable N = 88 N = 88
ACPRa (uncorrected) n 65 70
ETFb n 0 0
LCFc n 4 4
LPFd n 9 6
New infections (with PCR) n 9 7
Recrudescences (with PCR) n 4 3
No treatment outcome (loss to
follow-up or withdrawn) n
10 8












Cohort 2: Artesunate-amodiaquine Montepuez Dondo
Variable N = 87 N = 87
ACPRa (uncorrected) n 81 78
ETFb n 0 0
LCFc n 0 0
LPFd n 0 0
New infections (with PCR) n 0 0
Recrudescences (with PCR) n 0 0
No treatment outcome (loss to
follow up or withdrawn) n
6 9
PP day-28 efficacy (PCR-uncorrected)
n/N (95%CI)
81/81 (100) [NA] 78/78 (100) [NA]
PP day-28 efficacy (PCR-corrected)
n/N (95%CI)
81/81 (100) [NA] 78/78 (100) [NA]
aACPR:adequate clinical and parasitological response; bETF: early treatment failure; c
not applicable.
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study-specific database created using open clinica software
(OpenClinica Enterprise - Electronic Data Capture Soft-
ware for Clinical Trials version 3.1.2, OpenClinica LLC,
Waltham, MA, USA). Two populations were defined
for the analysis: the intent-to-treat (ITT) population
(safety population) comprised all patients who re-
ceived ≥ one dose of study medication and underwent
at least one post-baseline safety assessment. Efficacy
was calculated in the according-to-protocol population
(ATP), which included all patients fulfilling the proto-
col eligibility criteria, having completed the three-day
course of study medication, accomplishing the day-28
assessment and having an evaluable PCR in case of
recurrent parasitaemia. Cure rates were calculated as
the number of patients with clinical and parasito-
logical cure by day 28 divided by the total number of
patients who could be evaluated. Additionally, Kaplan-
Meier estimates of the cumulative risk of failure wereohort (AL or ASAQ) at various sites in Mozambique
Study site
Chokwe Manhiça Tete TOTAL
N = 86 N = 89 N = 88 N = 439
70 62 68 335
1 0 0 1
0 0 0 8
6 5 4 30
4 3 2 25
2 2 2 13

















Chokwe Manhiça Tete TOTAL
N = 87 N = 0 N = 0 N = 261
73 NA NA 232
0 NA NA 0
0 NA NA 0
1 NA NA 1
0 NA NA 0
1 NA NA 1
13 NA NA 28
73/74 (98.6)
[92.7-99.9]




NA NA 232/233 (99.6)
[97.6-99.9]
LCF: late clinical failure; dLPF: late parasitological failure; ePP: per protocol; NA:
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follow-up and study withdrawals were censored on the
last day of follow-up. Cases with re-infections were
also censored from the analysis. Statistical analyses
were done with Stata 13 (Stata Corp, College Station,
TX, USA), and the statistical significance level was set
at 5%. No formal comparisons were made between the
two study cohorts.Sample size calculations
The only available published data regarding the efficacy
of the two studied ACT in Mozambique come from pre-
vious studies conducted in Manhiça, where AL was
shown to have an efficacy ranging from 96.9% [13] to
over 98% [12] and ASAQ of 97.2% [10]. Sample size cal-
culations were based on WHO-proposed methodologies
[14] using a slightly more conservative expected efficacy
estimate (95%) and a level of precision around the esti-
mate of 5%. To achieve this, and with an expected loss
to follow-up rate of 20% on day 28, a minimum 87 pa-
tients would need to be recruited at each of the sites and
for each of the two study arms.Ethical considerations
The protocol was approved by the National Mozambican
Ethics Review Committee (Ref 134/CNBS/11) and the
Hospital Clínic of Barcelona Ethics Review Commit-
tee. The trial was conducted according to Good Clin-
ical Practice guidelines. Written consent was obtained
from the parents/guardians of the study children. The
clinical-trial identifier is NCT02168569 (http://www.
clinicaltrials.gov).Figure 2 Kaplan Meier curves showing the treatment success cumula
uncorrected) in the ATP population.Results
Trial profile and baseline characteristics
Between June 2011 and January 2012, both cohort 1
(AL) and cohort 2 (ASAQ) were recruited and followed
up to 28 days. Some 2,587 febrile children were screened
for cohort 1, of which 439 (16.9%) ended up being re-
cruited and 335 (76.3%) completed the study, with or
without a recurring parasitaemia. For cohort 2, 2,154 fe-
brile children were screened, 261 (12.1%) recruited and
232 (89.0%) successfully completed the study, with or
without a recurring parasitaemia (Figure 1). Main rea-
sons for exclusion in both cohorts was the absence of
malaria parasites at screening and/or the presence of
concomitant illnesses. The ITT and ATP populations for
cohort 1 included 439 and 335 individuals, respectively,
whereas for cohort 2 these numbers were 261 and 232,
respectively. Table 1 summarizes the baseline character-
istics for both cohorts, which were comparable in terms
of gender, mean age, weight, and malarial infection.
Efficacy
During the 28-day follow-up period, 66 patients (cohort 1;
15%) and 28 patients (cohort 2; 10.7%) did not successfully
complete the study on account of loss to follow-up, with-
drawal of consent or other protocol violations (Figure 1).
Table 2 and Figures 2 and 3 summarize both cohort
1 and cohort 2 treatment outcomes. The day-28 PCR-
uncorrected cure rate (i.e., the proportion of patients with
ACPR, ATP population) was 89.6 (335/374; 95% CI 86.0-
92.5) for AL, and 99.6 (232/233; 95% CI 97.6-99.9) for
ASAQ. Of the 38 cases of recurring parasitaemia in cohort
1, 25 (65.8%) proved to be new infections according to
PCR, yielding a day-28 PCR-corrected cure rate of 96.0tive proportion for each treatment cohort until day 28 (PCR
Figure 3 Kaplan Meier curves showing the treatment success cumulative proportion for each treatment cohort until day 28
(PCR-corrected) in the ATP population.
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curring parasitaemia was detected, which proved to be a
recrudescence of the original infection according to PCR.
Thus, day-28 PCR-corrected cure rate was identical to the
uncorrected one (99.6 [232/233; 95% CI 97.6-99.9]). All
patients in both cohorts cleared their parasitaemia by day
3 following treatment, 100% patients treated with ASAQ
by the end of the first 24 hours of follow-up, while 5.0%
(22/439) of the patients treated with AL took longer than
24 hours to clear parasitaemia (of these, 77.2% [17/22]
cleared parasitaemia on day 2, while 22.7% [5/22] on
day 3).Figure 4 Kaplan Meier curve showing time to negative parasitaemiaTolerability and safety
Fever, present at recruitment in about three-quarters
of all study patients, receded rapidly during the first
72 hours of follow-up, with all patients being afebrile by
day 7 of follow-up (Figures 4 and 5). Tolerability of the
two drugs, as judged by solicited adverse events during
drug intake, was good (Table 3). Some patients reported
vomiting (20/439, 4.5% in the AL cohort; 25/261, 9.6%
in the ASAQ group) during the three days of treatment,
and the occurrence of other solicited adverse events was
rare. All the vomiting episodes (with the exception of
two episodes in different children, both occurring in theaccording to study cohorte.
Figure 5 Proportion of children with fever (axillary temperature ≥37.5°C) according to day of visit and treatment cohort.
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after >1 hour post treatment, deemed unrelated to the
study drug) occurred within the first 30 minutes of treat-
ment, and thus required re-dosing. No patient had re-
peated vomiting episodes, and no rescue treatment was
required on account of vomiting. Six urticarial-like epi-
sodes (2/6 [33.3%] in the AL group, 4/6 [66.6%] in the
ASAQ group) occurred in both groups, being all of them
self-limited, transient and of mild nature. In the majority
of these cases (5/6; 83.3%) these events were judged
unrelated to the study drug, as alternative explanationsTable 3 Cumulative adverse events related to tolerability dur
(AL or ASAQ) at various sites in Mozambique
Cohort 1: Artemether-lumefantrine Montepuez Dondo
Variable N = 88 N = 88
Vomiting post dosing 1,2 or 3 n (%) 1 (1.1) 4 (3.2)
Diarrhoea n (%) 0 (0) 0 (0)
Weakness n (%) 0 (0) 0 (0)
Pruritus n (%) 0 (0) 0 (0)
Urticaria n (%) 1 (1.1) 0 (0)
Cohort 2: Artesunate-amodiaquine Montepuez Dondo
Variable N = 87 N = 87
Vomiting post dosing 1,2 or 3 n (%) 11 (12.6) 3 (3.5)
Diarrhoea n (%) 0 (0) 0 (0)
Weakness n (%) 0 (0) 0 (0)
Pruritus n (%) 0 (0) 0 (0)
Urticaria n (%) 0 (0) 0 (0)
*Urticaria in AL group deemed NOT related with study medication in both cases.
**Urticaria in AS-AQ deemed related to study medication in one of these 4 cases.
NA: Not applicable.(“atopy”; “eczema”; “scabies-related rash” (twice); “viral
rash”) were provided, although in one case (16.7%; post
AQAS), investigators deemed it “possibly” drug-related,
and the skin manifestations disappeared rapidly without
requiring any treatment.
Haemoglobin recovery from day 0 to day 28 occurred
slowly in both groups (mean increase in the AL cohort
being 1.0 (SD 4.2) and in the ASAQ cohort being 1.6
(SD 1.7) (Table 4). Seven serious adverse events (SAE)
were documented in the study: four in the AL group
(three severe malaria cases and a Kwashiorkor withing the three days of treatment for both study cohorts
Study site
Chokwe Manhiça Tete TOTAL
N = 86 N = 89 N = 88 N = 439
1 (1.1) 10 (11.2) 4 (3.2) 20 (4.5)
0 (0) 0 (0) 1 (1.1) 1 (0.2)
0 (0) 0 (0) 1 (1.1) 1 (0.2)
0 (0) 0 (0) 0 (0) 0 (0)
0 (0) 1 (1.1) 0 (0) 2 (0.5)*
Chokwe Manhiça Tete TOTAL
N = 87 N = 0 N = 0 N = 261
11 (12.6) NA NA 25 (9.6)
6 (6.9) NA NA 6 (2.3)
3 (3.5) NA NA 3 (1.1)
2 (2.3) NA NA 2 (0.8)
4 (4.6) NA NA 4 (0.9)**
Table 4 Change in haemoglobin (g/dL) (difference day 0 vs day 28) according to study cohort (AL or ASAQ) at various
sites in Mozambique
Study site
Variable Montepuez Dondo Chokwe Manhiça Tete TOTAL
Cohort 1
(artemether-lumefantrine)
Change in haemoglobin g/dL
(diff. day 28 vs. day 0) arithmetic
mean (SD) [n]
1.2 (1.8) [71] 1.7 (2.0) [75] 1.3 (2.2) [72] 0.5 (1.9) [73] 0.3 (8.6) [69] 1.0 (4.2) [360]
Cohort 2
(artesunate-amodiaquine)
Change in Haemoglobin g/dL
(diff. D28 vs. D0) Arithmetic
mean (SD) [n]
1.9 (1.5) [83] 1.8 (1.8) [78] 0.9 (1.6) [76] N/A N/A 1.6 (1.7) [237]
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severe malaria cases one of which with concomitant
severe pneumonia), none deemed by the investigators
related to the study drugs. Six of the seven SAEs re-
covered completely, but an 11-month-old female child
in the Montepuez site died after a severe malaria epi-
sode, which resolved adequately at hospital. The death
occurred at home, on the third day of follow-up, and
according to the verbal autopsy subsequently performed,
appeared related to the uncontrolled administration of
traditional medicine.
Discussion
This study describes the 28-day in vivo efficacy of AL
and ASAQ across several sentinel sites in Mozambique.
These five sites were thought to be a good geographical
representation of the variability of malaria endemicity
throughout the country. All sites followed the standard,
WHO-recommended, in vivo efficacy protocol [14], in-
cluding the use of molecular techniques to differentiate
a recurring parasitaemia and a recrudescence or a new
infection [17]. Although it was not possible to test the
second combination (ASAQ) in all five sites, the results
presented confirm that both drugs remain efficacious
and well-tolerated regimens in Mozambique. In this
study, both drugs appeared to be safe and well-tolerated,
perhaps with the exception of a non-negligible incidence
of vomiting associated with the use of ASAQ, something
that has previously been reported in relation to the use
of amodiaquine on its own [18] or in combination with
artesunate [19,20]. Haemoglobin recovery from day 0 to
day 28 occurred swiftly in both cohorts and in a compar-
able manner to what other authors have described when
using these two drugs [10], and the occurrence of other
AEs or SAEs was rare. These reassuring data add to the
well-documented, good safety profiles of ACT.
In terms of efficacy, PCR-corrected cure rates for AL
(96.0%) and ASAQ (99.6%) remain high and adequate
according to WHO recommendations. As this study was
not designed as a direct comparison between the two
cohorts, caution needs to be taken in terms of compa-
ring both drugs’ efficacy estimates. This relatively lowerefficacy of AL, in comparison to ASAQ and also to pre-
vious historical estimates [10,12,13], could be a first sig-
nal of a potential decline of AL efficacy in Mozambique.
However, the confirmation that all patients in the AL
group had cleared parasitaemia by day 3 (72 hr post
treatment), a proxy harbinger of artemisinin resistance
as proposed by some authors [21,22], is reassuring.
However, other factors such as the challenges in directly
observing the evening treatment in the group receiving
AL, may have also contributed to these differences. Con-
tinuous monitoring throughout the country of AL in vivo
efficacy is thus necessary to allow an early detection of
further signs of AL declining efficacy.
Conclusion
This multisite efficacy study conducted in five sites across
Mozambique confirmed that AL and ASAQ are still
highly efficacious and well tolerated. Studies such as this
one should be replicated regularly nationwide to conti-
nuously monitor the efficacy of these drugs and to ra-
pidly detect any potential signs of declining efficacy to
ACT, the mainstay of malaria treatment.
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